Table 2.
Characteristics of the healthy individuals included in the vortioxetine pooled population pharmacokinetic analysis
| N | Mean | S.D. | Minimum | Median | Maximum | |
|---|---|---|---|---|---|---|
| Age (year) | 887 | 33.7 | 13.3 | 18 | 30 | 78 |
| Weight (kg) | 887 | 73.6 | 12.3 | 45.2 | 73.3 | 112 |
| Height (cm) | 887 | 172 | 9 | 144 | 173 | 203 |
| BMI (kg/m2) | 887 | 24.8 | 3.3 | 15.1 | 24.8 | 35.5 |
| Lean body-weight (kg) | 887 | 55.8 | 8.8 | 34.8 | 56.3 | 84.5 |
| Albumin (g/L) | 887 | 46.0 | 3.0 | 36 | 46 | 55 |
| ALAT (IU/L) | 881 | 23.4 | 12.4 | 5 | 20 | 128 |
| ASAT (IU/L) | 881 | 21.8 | 7.5 | 10 | 21 | 145 |
| Bilirubin (μmol/L) | 869 | 12.2 | 5.7 | 3 | 11 | 52 |
| Creatinine clearance (mL/min.) | 887 | 122 | 28 | 41.9 | 120 | 223 |
| Counts (frequency) | |
|---|---|
| Males:Females | 627:260 |
| Phenotype CYP2D6 UM:EM:IM:PM | 21:540:276:38 |
| Missing phenotype CYP2D6 data | 12 |
| Phenotype CYP2C19 EM:IM:PM | 548:282:44 |
| Missing phenotype CYP2C19 data | 13 |
| Phenotype CYP2C9 – EM:IM:PM | 786:17:0 |
| Missing phenotype CYP2C9 data | 84 |
| White | 657 |
| Black or African American | 98 |
| Asian | 129 |
| Native Hawaiian or Other Pacific Islander | 1 |
| American Indian or Alaska Native | 1 |
| Missing race | 1 |
| Non-Hispanic:Hispanic | 366:298 |
| Missing ethnicity data | 223 |
| Region EU:US:Japan | 327:444:116 |
S.D., standard deviation; UM, ultra metaboliser; EM, extensive metaboliser; IM, intermediate metaboliser; PM, poor metaboliser.